- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00955032
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease (ReStore)
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease.
Study Overview
Status
Conditions
Detailed Description
Apathy is a syndrome characterized by a primary lack of motivation and it manifests in three domains: behavioral (lack of effort and productivity, dependence on others for structuring daily activities), cognitive (loss of interest in new experiences, lack of concern for one's problems) and affective (flattened affect and lack of response to positive or negative events). Apathy has been consistently attributed to functional disturbance of neural systems involving mesial frontal and the anterior cingulate cortex (ACC), an area with reciprocal connections with limbic, frontal cortices and the basal ganglia.
Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive tool used to manipulate activity in specific brain neural circuits through the skull and, in turn, induce short-term (milliseconds) and long-term (minutes to hours) changes in behavior. The duration of effect depends on the stimulation mode. Several studies have now demonstrated that rTMS may facilitate or modulate behavior beyond the actual stimulation. rTMS of the mid-dorsolateral frontal cortex (MDLFC) has been used to treat depression presumably because of its modulatory effect on the fronto-cingulate system (MDLFC and the ACC circuitry). Studies have shown that rTMS of the left MDLFC modulates the blood flow response in the ACC. We therefore hypothesize that high-frequency rTMS of the left MDLFC will also improve apathy in PD.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of "probable" PD, defined by the presence of at least 2 out of 3 cardinal motor features of PD (resting tremor, rigidity, and bradykinesia, plus a sustained and significant response to dopaminergic treatment);
- age 30 or over; and
- on stable medications for at least 30 days.
Exclusion Criteria:
- features suggestive of other causes of parkinsonism/ parkinson-plus syndromes;
- history of deep brain stimulation or ablation surgery, significant headaches, epilepsy or seizure disorder, mass brain lesions, or major head trauma leading to loss of consciousness of any length;
- family (1st degree relatives) history of epilepsy;
- evidence for dementia;
- presence of contraindications for functional magnetic resonance imaging (fMRI);
- history of schizophrenia, schizoaffective disorder, other psychosis, rapid-cycling bipolar illness, alcohol/drug abuse within the past year;
- need for rapid clinical response due to conditions such as initiation, psychosis, or suicidality;
- unstable medical condition such as diabetes, cardiac disease, hypertension;
- pregnancy; and
- colorblindness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High-Frequency Repetitive Transcranial Magentic Stimulation
High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz).
We will administer rTMS trains every 30 seconds for 25 minutes.
Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
|
In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz).
We will administer rTMS trains every 30 seconds for 25 minutes.
Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
Other Names:
|
Sham Comparator: Sham Repetitive Transcranial Magentic Stimulation
Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS.
Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex.
However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp.
We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
|
Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS.
Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex.
However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp.
We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Apathy Evaluation Scale (AES)
Time Frame: Pre-Tx; 10 days post tx
|
The apathy evaluation scale is a 14-item self-report questionaire that provides a quantitative estimate of apathy symptoms.
Items are given a score of 0-3, and a total score is summated using all items.
Scores may range between 0 and 42.
Higher scores are indicative of greater symptoms of apathy, and a score of 14 is suggestive of clinically significant symptoms.
|
Pre-Tx; 10 days post tx
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lille Apathy Rating Scale (LARS)
Time Frame: Pre-Tx; 10 days post-tx
|
The Lille Apathy Rating Scale (LARS) is a 33-item interviewer administered structured questionaire designed to assess level of apathetic symptoms.
The first 3 items are scored from -2 to +2, while the remainder items are scored from -1 to +1.
Scores can range between -36 to +36.
The more positive the score, the greater level of apathy symptoms.
|
Pre-Tx; 10 days post-tx
|
Beck Depression Inventory-Second Edition (BDI-II)
Time Frame: Pre-Tx; 10 days post-tx
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-item self-report questionaire that measures depressive symptoms.
Each item is scored on a scale of 0-3, and items are summated to yield a total score.
A higher score is indicative of greater symptoms of depression.
Total scores may range between 0 and 63.
A score greater than or equal of 14 is suggestive of clinically significant symptoms.
|
Pre-Tx; 10 days post-tx
|
Hamilton Depression Rating Scale (HAM-D)
Time Frame: Pre-Tx; 10 days post-tx
|
The Hamilton Depression Rating Scale (HAM-D) is a 24-item interviewer administered structure questionaire designed to assess symptoms of depression.
Items are scored with a range of 0-4, though 11 of the items are scored between 0 and 2. A total score is then calculated of all items which can range from 0 to 74.
A higher score is indicative of more depressive symptoms, and a lower score post-tx is indicative of better outcome.
|
Pre-Tx; 10 days post-tx
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Hubert H Fernandez, M.D., University of Florida
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0004762006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on High-Frequency Repetitive Transcranial Magnetic Stimulation
-
Universidade Federal de PernambucoUnknownParkinson DiseaseBrazil
-
Taipei Hospital, Ministry of Health and WelfareRecruitingDementia | Cognitive Impairment, MildTaiwan
-
VA Office of Research and DevelopmentRalph H. Johnson VA Medical CenterRecruiting
-
Universidade Federal de PernambucoCompleted
-
Kessler FoundationRecruitingSpinal Cord InjuriesUnited States
-
Universidade Federal de PernambucoUnknownSpinal Cord InjuriesBrazil
-
Cairo UniversityNot yet recruitingPatients With Multiple Sclerosis
-
University Hospital, CaenCompletedDepression | SchizophreniaFrance
-
Beth Israel Deaconess Medical CenterCompletedEpilepsy, Temporal LobeUnited States
-
University of RegensburgCompleted